middle.news

Why Did Proteomics International’s Shares Surge? Medicare Pricing and Product Wins Explained

5:01pm on Tuesday 2nd of December, 2025 AEDT Healthcare
Read Story

Why Did Proteomics International’s Shares Surge? Medicare Pricing and Product Wins Explained

5:01pm on Tuesday 2nd of December, 2025 AEDT
Key Points
  • US Medicare sets reimbursement price for PromarkerD at US$390.75
  • PromarkerD and PromarkerEso launched in Australia with initial sales recorded
  • New data shows OxiDx biomarker linked to improved racehorse performance
  • Company confirms compliance with ASX continuous disclosure rules
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Proteomics International Laboratories (ASX:PIQ)
OPEN ARTICLE